Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Neumora Therapeutics, Inc. - Common Stock (NQ:NMRA)

2.415 +0.175 (+7.81%)
Streaming Delayed Price Updated: 12:30 PM EST, Dec 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Neumora Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Neumora Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
From Neumora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Neumora Therapeutics to Participate in Upcoming Conferences in November
From Neumora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-898
From Neumora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Neumora Therapeutics Announces Class-Leading Weight Loss Demonstrated with NMRA-215 in Preclinical Diet-Induced Obesity Model
From Neumora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Neumora Therapeutics to Host Virtual R&D Day on October 27
From Neumora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Neumora Therapeutics to Participate in Upcoming Conferences in September
From Neumora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Neumora Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
From Neumora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Neumora Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025
From Neumora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861
From Neumora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
From Neumora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Neumora Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025
From Neumora Therapeutics, Inc.
Via GlobeNewswire
News headline image
NMRA Investors Have Opportunity to Lead Neumora Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
Final NMRA Deadline Reminder: April 7, 2025 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer &amp; Check, LLP
RADNOR, PA - April 7, 2025 (NEWMEDIAWIRE) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Neumora... 
Via TheNewswire.com
Topics Lawsuit
News headline image
Final NMRA Deadline Reminder: April 7, 2025 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
News headline image
Faruqi & Faruqi Reminds Neumora Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 7, 2025 - NMRA
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
NMRA Deadline in 4 Days: Kessler Topaz Meltzer & Check, LLP Reminds Neumora Therapeutics, Inc. (NMRA) Investors of Filing Deadline in Class Action Lawsuit
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
News headline image
NMRA Deadline in 4 Days: Kessler Topaz Meltzer &amp; Check, LLP Reminds Neumora Therapeutics, Inc. (NMRA) Investors of Filing Deadline in Class Action Lawsuit
RADNOR, PA - April 3, 2025 (NEWMEDIAWIRE) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Neumora... 
Via TheNewswire.com
Topics Lawsuit
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Neumora Therapeutics, Inc of Class Action Lawsuit and Upcoming Deadlines - NMRA
From Pomerantz LLP
Via GlobeNewswire
News headline image
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Neumora Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
NMRA DEADLINE ALERT: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Neumora Therapeutics, Inc. Securities Fraud Class Action Lawsuit
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
NMRA DEADLINE ALERT: Kessler Topaz Meltzer &amp; Check, LLP Announces Deadline in Neumora Therapeutics, Inc. Securities Fraud Class Action Lawsuit
RADNOR, PA - April 1, 2025 (NEWMEDIAWIRE) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Neumora... 
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
NEUMORA THERAPEUTICS, INC. (NASDAQ: NMRA) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Neumora Therapeutics, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
NMRA DEADLINE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Neumora Therapeutics, Inc. Investors to Secure Counsel Before Important April 7 Deadline in Securities Class Action First Filed by the Firm – NMRA
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
Neumora Therapeutics, Inc. (NMRA) Investors: April 7, 2025 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
News headline image
Neumora Therapeutics, Inc. (NMRA) Investors: April 7, 2025 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer &amp; Check, LLP
RADNOR, PA - March 30, 2025 (NEWMEDIAWIRE) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Neumora... 
Via TheNewswire.com
Topics Lawsuit
News headline image
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Neumora Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Neumora Therapeutics, Inc of Class Action Lawsuit and Upcoming Deadlines - NMRA
From Pomerantz LLP
Via GlobeNewswire
News headline image
Neumora Therapeutics, Inc. (NMRA) Shareholder Reminder: Kessler Topaz Meltzer & Check, LLP Reminds NMRA Investors of Securities Fraud Class Action Lawsuit
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
Neumora Therapeutics, Inc. (NMRA) Shareholder Reminder: Kessler Topaz Meltzer &amp; Check, LLP Reminds NMRA Investors of Securities Fraud Class Action Lawsuit
RADNOR, PA - March 28, 2025 (NEWMEDIAWIRE) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Neumora... 
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
NMRA Deadline: Rosen Law Firm Urges Neumora Therapeutics, Inc. (NASDAQ: NMRA) Stockholders with Losses to Contact the Firm for Information About Their Rights in Securities Class Action First Filed by the Firm
From The Rosen Law Firm, P.A.
Via Business Wire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.